US EditionPublished • loading... • Updated
Myasthenia Gravis Drug Shows Benefits in Wider Range of Patients
Summary by Anti-Aging, Acupuncture and Health News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Myasthenia Gravis Drug Shows Benefits in Wider Range of Patients
(MedPage Today) — SAN FRANCISCO — Intravenous efgartigimod (Vyvgart) met its primary endpoint in adults with acetylcholine receptor (AChR) antibody-negative myasthenia gravis, the ADAPT SERON trial showed. At week 4, Myasthenia Gravis Activities… Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118255 Author : Publish date : 2025-10-31 15:11:00 Copyright for syndicated content belongs to the linked Source. The post Myasthenia Gra…
Newly Unveiled EPIC Trial Pins Myasthenia Gravis Medications Nipocalimab Against Efgartigimod for Efficacy | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A groundbreaking trial compares nipocalimab and efgartigimod for treating generalized myasthenia gravis, promising new insights for patient care.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
